---
title: "CalciMedica | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295527848.md"
datetime: "2026-08-11T11:16:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295527848.md)
  - [en](https://longbridge.com/en/news/295527848.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295527848.md)
---

# CalciMedica | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.45, missing the estimate of USD -0.29.

EBIT: As of FY2026 Q2, the actual value is USD -4.391 M.

#### Cash Position

CalciMedica, Inc. reported cash and cash equivalents of $18,617 thousand as of June 30, 2026, an increase from $11,520 thousand as of December 31, 2025.

#### Research and Development (R&D) Expenses

R&D expenses were $2,102 thousand for the three months ended June 30, 2026, a decrease from $4,052 thousand for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $5,587 thousand, down from $8,276 thousand for the six months ended June 30, 2025, primarily due to reduced preclinical and clinical trial activities, consultant and personnel costs, and chemistry, manufacturing, and controls activities.

#### General and Administrative (G&A) Expenses

G&A expenses totaled $1,910 thousand for the three months ended June 30, 2026, compared to $2,569 thousand for the three months ended June 30, 2025. For the six months ended June 30, 2026, G&A expenses were $4,036 thousand, a decrease from $4,842 thousand for the six months ended June 30, 2025, primarily attributable to lower personnel and consultant costs.

#### Other Income (Expense)

Total other expense was - $3,640 thousand for the three months ended June 30, 2026, contrasting with total other income of $665 thousand for the same period in 2025. For the six months ended June 30, 2026, total other income was $6,947 thousand, significantly higher than $2,120 thousand for the six months ended June 30, 2025, primarily reflecting an increase in income from changes in the fair value of the Company’s financial instruments. The change in fair value of financial instruments was - $3,600 thousand for Q2 2026 versus $500 thousand for Q2 2025, and $7,200 thousand for the six months ended June 30, 2026 versus $2,200 thousand for the prior year period. Interest expense was - $325 thousand for Q2 2026 and - $644 thousand for the six months ended June 30, 2026, while interest income was $54 thousand for Q2 2026 and $160 thousand for the six months ended June 30, 2026.

#### Net Income (Loss)

CalciMedica, Inc. reported a net loss of - $7,652 thousand for the three months ended June 30, 2026, compared to a net loss of - $5,956 thousand for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was - $2,676 thousand, an improvement from a net loss of - $10,998 thousand for the six months ended June 30, 2025. The net loss per share was - $0.45 for Q2 2026 and - $0.16 for the six months ended June 30, 2026.

#### Outlook / Guidance

CalciMedica, Inc. anticipates its current cash and cash equivalents to fund operating plans into the second half of 2027. The company expects to release Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and submit the CM5480 Investigational New Drug (IND) application both by mid-2027. The initiation of the planned Phase 2b trial for Auxora in acute pancreatitis (AP) is contingent upon additional financing.

### Related Stocks

- [CALC.US](https://longbridge.com/en/quote/CALC.US.md)

## Related News & Research

- [CalciMedica Q2 net loss widens](https://longbridge.com/en/news/295526807.md)
- [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md)
- [Gabelli Equity Trust declares $0.15 per share cash distribution for Q3 2026](https://longbridge.com/en/news/295684402.md)
- [Eidesvik Offshore to present Q2 2026 results in digital briefing](https://longbridge.com/en/news/295931470.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/295955673.md)